

RECEIVED
CENTRAL FAX CENTER

APR 29 2005


PTO/SB/21 (09-04)


Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM	Application Number	10/616,279
	Filing Date	July 8, 2003
	First Named Inventor	HARKINS et al.
	Art Unit	1644
	Examiner Name	M. Szporka
(to be used for all correspondence after initial filing)		
Total Number of Pages In This Submission	3	Attorney Docket Number 51791AUSD1

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
Remarks This reply is being submitted via facsimile to the USPTO Central Fax No. (703) 872-9306.		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	BERLEX BIOSCIENCES	
Signature		
Printed name	Wendy L. Washtien, Ph.D.	
Date	April 29, 2005	Reg. No. 36,301

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:	
Signature	
Typed or printed name	Mary Ann Flores
Date	April 29, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Case 51791AUSD1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER
APR 29 2005

In re Application of :
Harkins et al. :
Serial No. 10/616,279 : Group Art Unit 1644
Filed July 8, 2003 : Examiner: M. Szperka
For DNA ENCODING A NOVEL RG1 POLYPEPTIDE

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESTRICTION REQUIREMENT UNDER 35 U.S.C. 121

This communication is in response to the Restriction Requirement dated April 1, 2005.

The Examiner has required restriction to one of the following groups:

- Group I. Claims 24-29, 31-34, and 44, drawn to antibodies and immunoconjugates.
- Group II. Claim 35, drawn to a method of selectively destroying a cell.
- Group III. Claim 36, drawn to a method of treating a disease with an immunoconjugate.
- Group IV. Claim 37, drawn to a method of treating a disease by administering a ribozyme.

51791AUSD1rr